Vincent RIALLE. Maître de conférences-praticien hospitalier, Dr GBM, Dr éthique médicale et biologique

Similar documents
Andalusian Agency for Health Technology Assessment (AETSA)

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Health Technology Assessment and the European Network for HTA

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

WHO Workshop, Bangkok, Health Technology Assessment

Adaptation of HTA reports: an effective way to use limited resources?

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

EMA experience with the review of digital technology proposals in medicine development programmes

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

December Eucomed HTA Position Paper UK support from ABHI

Health Technology Assessment (HTA) Dr Hamid Ravaghi

Issues in Emerging Health Technologies Bulletin Process

ABHI Response to the Kennedy short study on Valuing Innovation

Security and Risk Assessment in GDPR: from policy to implementation

Translational scientist competency profile

Precision Public Health Call for Proposals

Medical Education Activities

IHT at the HTAi A parallel workshop June 2005 Rome. Introduction Andrew Webster Programme Director

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy

Prioritisation of potentially obsolete technologies

Digital Medical Device Innovation: A Prescription for Business and IT Success

Horizon Societal Challenge 1: Health, demographic change and wellbeing. Jeremy Bray DG Research & Innovation European Commission

Alberta Health Services and Advancing Uptake of HTA & Innovation

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

EU Cooperation on Health Technology Assessment

Innovation and the Changing Practice of Medicine

Fifth Framework Programme for Research, Technological Development and Demonstration Quality of Life and Management of Living Resources

28 March Report of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health.

Health Technology Assessment of innovative medical devices

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

Computers and Medicine

& Medical Tourism. DIHTF - Dubai 20 th -21 st Feb 2018 V S Venkatesh -India

Digital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver

Clinical and Organizational Innovation In Healthcare Organizations

e-care Living Lab - 5 avenue du Grand Sablon La Tronche - FRANCE Tel: +33 (0)

Pharma Session 4: Digital health your health on (the) line

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

Human factors and design in future health care

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

INAHTA Working Group Ethical Issues in HTA

envision workshop Designing for Change The Exam Process in 2030 American Academy of Ophthalmology 2015

Health Technology Assessment (HTA): A Primer for Procurement Professionals

USTGlobal. Internet of Medical Things (IoMT) Connecting Healthcare for a Better Tomorrow

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use

Decision Determinants Guidance Document

Implementation of Systems Medicine across Europe

ESA Activities in Health in support of the Sustainable Development Goals and WHO Leadership Priorities

mission why join? our members

NREP Conference 7 10 April 2014 Salt Lake City - UT, USA 08/10/2013 1

FDA Centers of Excellence in Regulatory and Information Sciences

TechARENA: MedTech. Is digital health dead? M. Kaiser Senior Manager Business Development SEMI Europe, SEMI Europe, Berlin, Germany

SENIOR CITIZENS ARE RIDING THE DIGITAL HEALTH WAVE

Impacts and Risks Caused by AI Networking, and Future Challenges

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

For Immediate Release. For More PR Information, Contact: Carlo Chatman, Power PR P (310) F (310)

Roche Pharma Report Relating to EUnetHTA HTA Core Model Applications for Pharmaceuticals. December 21 st 2014

Health Informatics. For further volumes:

Epilogue. Simona Rocchi Erasmus University, Centre for Environmental Studies, Rotterdam

Early HTA to inform value driven market access and reimbursement planning

EUROPE March Brussels, Belgium CALL FOR ABSTRACTS. Join Us at the Crossroads of Healthcare. DIAglobal.org/Europe2020 #DIAEurope2020

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

Digitalisation of the medicines lifecycle: challenges and opportunities

M-HEALTH APPS AND SELF-QUANTIFICATION TECHNOLOGIES ON THE RISE. OPPORTUNITIES AND RISKS FOR USE IN PRACTICE

Early awareness and alert (EAA) systems. EuroScan International Network: History and Impact

Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools

TRIPS and Access to Medicines. WR Briefing

Presented by Doris Ma Fat on behalf of the. Department of Health Statistics and Information Systems World Health Organization, Geneva

The prospective contribution and the global and integrated approach to pharmaceutical industry s new challenges.

Engineering for Health

Sanctions Guide At Risk Elements AUSTRALIAN SANCTIONS & EXPORT CONTROLS COMPLIANCE FORM OVERVIEW. Legal Services Corporate Services

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

CENTRAL VIRGINIA LEGAL AID SOCIETY, INC.

Package Architecture and Component Design for an Implanted Neural Stimulator with Closed Loop Control. Caroline K. Bjune

Processes and mechanisms for contextualizing scientific evidence Moving from HTA to HTPA?

Assessment element tables

About This Survey. General Concepts and Definitions

ANALYSIS OF HUMAN BREAST MILK AT MICROWAVE FREQUENCIES

End-to-End Infrastructure for Usability Evaluation of ehealth Applications and Services

The Exploratory Study for the Psychological Perception and User Attitude toward the Add-on Devices for the Elderly

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

The role of intelligent habitats in upholding elders in residence

How AI and wearables will take health to the next level - AI Med

Using European Joint HTAs in local settings to adopt or to adapt, that is

WRHA Supply Chain New Technology Workshop Supply Chain Forum November 17, 2010

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Health & Social Care Industrial Innovation

March 2018 CCG localities profile for Hertfordshire

02.03 Identify control systems having no feedback path and requiring human intervention, and control system using feedback.

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

Magnus Steigedal Director NTNU Health NTNU

USTGlobal. How Integrated Data and Technology Affect the Healthcare Ecosystem. UST Global Healthcare Contributed Article

The ESF Mission. ESF provides a common platform for its Member Organisations (MOs) in order to:

TECHNICAL EDUCATION SUBJECT BOOKLET

Missouri Educator Gateway Assessments

Summary HTA. Methods for assessment of innovative medical technologies during early stages of development. HTA-Report Summary

Health Innovations in Horizon 2020: the framework programme for research and innovation ( )

Transcription:

Vincent RIALLE Maître de conférences-praticien hospitalier, Dr GBM, Dr éthique médicale et biologique Responsable de l Unité Fonctionnelle ATMISS «Alzheimer, Technologie et Méthodes d'intervention Sanitaires et Sociales» CHU de Grenoble / Pôle de Santé Publique Vice-président de la Société Française de Technologies pour l Autonomie et de Gérontechnologie Vice-président du Centre National de Référence Santé à Domicile et Autonomie Laboratoire TIMC-IMAG UMR UJF/CNRS 5525 & CHU de Grenoble 1

Summary! Introduction " What do we talk about?! «!health technology!» «!true value!»! complexity " Quick review of definition, point of view, values! How to go beyond the admission of complexity " Proposition of a practical generic approach of assessment 2

Introduction What do we talk about? 3

4

Health 5

Health Technology «!Any intervention that may be used to promote health, to prevent, diagnose or treat disease or for rehabilitation or long-term care. This includes the pharmaceuticals, devices, procedures and organizational systems used in health care!» Wikipedia 6

Health Technologies according to! National Institute for Health and Clinical Excellence (NICE, Univ of Leeds) 1. medicines 2. medical devices (for example, hearing aids or inhalers) 3. diagnostic techniques (tests used to identify diseases) 4. surgical procedures (for example, repairing hernias) 5. health promotion activities (for example, ways of helping people with diabetes manage their condition). 7

Health Technologies according to! The Health Technology Assessment Handbook 1. Biological preparations: e.g. vaccines, gene therapy 2. Equipment, devices and supplies: e.g. pacemakers 3. Medical and surgical procedures: e.g. cognitive therapy 4. Diagnostic procedures and techniques: e.g. functional capacity 5. Presentation of knowledge: e.g. preventive health interviews 6. Support systems: e.g. telemedicine systems, electronic booking systems, drug selections, 7. Clinical laboratories and blood bank 8. Organisational and managerial systems: e.g. visiting nurse service 8

Health Technologies according to! Home Care Technology Association of America (HCTAA) (Technology for aging in the community] " Aging in Place «!is a broad term that defines living independently that is, living where the patient decides to live!» " Home care technology provides essential tools to permit aging in place on a widespread, cost-effective scale. " Access to compassionate and consistent care " Remote patient monitoring systems ( ) to collect and transmit the physiological data of patients with chronic diseases, such as diabetes, asthma, hypertension, and congestive heart failure. " TeleCare systems; TeleCare Centers 9

Health Technologies according to! Caring.com (Technology for aging in the community) 1. Communicate with others How can families be more proficient 2. Manage medications solutions ranging from phone-based products to in-home technological pill containers 3. Preserve safety Seniors want to stay in their homes, but their caregivers and relatives worry daily about how they re doing and whether they are safe there. 4. Enhance health wearable products, online health records and telepharmacy techniques 5. Simplify tasks Endless supply of products that help seniors with the everyday tasks 10

Scientific disciplines involved Example of gerontechnology (from JEMH van Bronswijk, 2008) Geron - technology 11

Health Technology Medical Devices (MD) # Assistive Technologies # Technologies for Aging in the Community (TAC) # 12

13

Values Case 1! Danish Centre for Health Technology Assessment " 5 domains of values Technology Patient 0rganization Economy Ethics Health Technology Assessment World Europe 2009 http://www.healthnetworkcommunications.com/2009/ hta/ 14

Values Case 2! European network for Health Technology Assessment (EUnetHTA) " Nine domains of values 1. Health problem and current use of the technology 2. Description and technical charac. of the technology 3. Safety 4. Effectiveness (mortality, morbidity, function, QoL, patient satisfaction) 5. Costs, economic evaluation 6. Ethical aspects 7. Organisational aspects 8. Social aspects 9. Legal aspects MethoTelemed: Users needs: Report on the results of Workshop One (oct 2009) 15

16

Health Technology Assessment " technology assessment in health care is a multidisciplinary field of policy analysis. It studies the medical, social, ethical, and economic implications of development, diffusion, and use of health technologys " International Network for Agencies in Health Technology Assessment 17

Health Technology Assessment " research-based, practice-oriented assessments of relevant available knowledge on the direct and intended consequences of technologies, as well as the indirect and unintended consequences " Society for Health Technology Assessment International (HTAi) 18

Assessment methods 19

Inherent complexity of the assessment of Technologies for living in the community! Origin of complexity " Technology involves services (social, medical ) " HATs includes world-objects world-objects: an object who shares one of its dimensions with the dimensions of the whole world "A satellite for speed, an atomic bomb for energy, the Internet for space, and nuclear waste for time...these are four examples of world-objects.» Michel Serres! Consequence " A number of possible indicators " A number of assessment methods 20

Necessity to share a common language to describe fiunctions and body structures, activities and social participation, and environnement factors 21

Magnitude Example of the clinical assessment phases! Pre-clinical studies " n vitro (test tube) and in vivo (animal or cell culture)! Phase 0 " exploratory! Phase I " first stage of testing in human subjects; small groups! Phase II " to assess how well the drug works; on larger groups (20-300)! Phase III " randomized controlled multicenter trials; large groups! Phase IV " Post marketing surveillance trials 22

23

Proposition for structuring complexity: The TEMSED approach! A two faceted approach " One fort the «!values!» multidimentionality : Axiology " One for the size and maturity of the study : Magnitude 1. Axiology Technology Ergonomics Medicine Society Economics Deontology 2. Magnitude Design: Research and development Phase I: technical aspects (reliability, robustness ) Phase II: relation between the user and the device Phase III: probing results in various terms Phase IV: economical viability and dissemination capacities 24

Two main dimensions 25

TEMSED general diagram Deontology Economics Axiology Ergonomics Medicine Society Technology Design Phase I Phase II Phase III Phase IV Magnitude Rialle V, Vuillerme N et Franco A. Outline of a general framework for assessing e-health and gerontechnology applications: Axiological and diachronic dimensions. Gerontechnology, 2010, 9 (2): 245. 26

! TEMSED Discussion - conclusion " Provides a framework For gathering complimentary assessment traditions For helping to systematise assessment " Is not a definite model stricto sensus " Is intended to be used, namely By the French National Reference Center for home care and autonomy (CNR SDA) By the French Chapter of ISG " Is not intended to provide all solutions regarding assessment methods " May be the summary of a vast handbook of evaluation to write together 27

28